Mon panier

FITC-Labeled Human Siglec-3 / CD33 Protein, Fc Tag

Numéro de produit/spécification
Prix
Qté
CD3-HF256-25ug
$330.00
CD3-HF256-200ug
$2245.00
ETA of in-stock products:2 business days
Total des articles Montant du produit$ 0

Détails du produit

  • Synonyms

    CD33, SIGLEC3, gp67

  • Source

    FITC-Labeled Human Siglec-3, Fc Tag (CD3-HF256) is expressed from human 293 cells (HEK293). It contains AA Asp 18 - His 259 (Accession # AAH28152.1). It is the FITC labeled form of Human Siglec-3, Fc Tag (Cat. No. CD3-H5257).

    Predicted N-terminus: Asp 18

    Request for sequence

  • Molecular Characterization

    Siglec-3 Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a human IgG1 Fc tag at the C-terminus.

    The protein has a calculated MW of 52.9 kDa. The protein migrates as 70-90 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Conjugate

    FITC

    Excitation source: 488 nm spectral line, argon-ion laser

    Excitation Wavelength: 488 nm

    Emission Wavelength: 535 nm

  • Labeling

    The primary amines in the side chains of lysine residues and the N-terminus of the protein are conjugated with FITC using standard chemical labeling method. The residual FITC is removed by molecular sieve treatment during purification process.

  • Protein Ratio

    The FITC to protein molar ratio is 2-4.

  • Purity

    >90% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Shipping and Storage

    This product is shipped at ambient temperature.

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please protect from light and avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • SDS-PAGE

    Siglec-3 SDS-PAGE

    FITC-Labeled Human Siglec-3, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.

  • Bioactivity-ELISA

     Siglec-3 ELISA

    Immobilized Human Siglec-3 Antibody at 1 μg/mL (100 μL/well) can bind FITC-Labeled Human Siglec-3, Fc Tag (Cat. No. CD3-HF256) with a linear range of 0.313-5 μg/mL (QC tested).

    Protocol

Avis des utilisateurs
Publier un commentaire

Introduction de fond

Myeloid cell surface antigen CD33 is also known as SIGLEC3, Siglecs (sialic acid binding Ig­like lectins) and GP67, is a single-pass type I membrane protein which belongs to the immunoglobulin superfamily and SIGLEC (sialic acid binding Ig-like lectin) family. Human CD33 / Siglec-3 cDNA encodes a 364 amino acid (aa) polypeptide with a hydrophobic signal peptide, an N-­terminal Ig-­like V­-type domain, one Ig­-like C2-­type domains, a transmembrane region and a cytoplasmic tail. CD33 / Siglec-3 usually considered myeloid-specific, but it can also be found on some lymphoid cells. In the immune response, CD33 / Siglec-3 may act as an inhibitory receptor upon ligand induced tyrosine phosphorylation by recruiting cytoplasmic phosphatase(s) via their SH2 domain(s) that block signal transduction through dephosphorylation of signaling molecules. CD33 / Siglec-3 induces apoptosis in acute myeloid leukemia.

Progrès de frontière

 
Progrès du développement médicamenteux
  • Nom anglais:

    Myeloid cell surface antigen CD33

  • Catégorie:

  • Nombre de médicaments répertoriés:

    1 Détails

  • Nombre de médicaments cliniques:

    44 Détails

  • Étape de développement la plus élevée:

    Approved

Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs
  • Contexte